Symbols / GOVX Stock $1.17 +2.63% GeoVax Labs, Inc.
GOVX (Stock) Chart
About
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms in the United States. The company is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. It also developing GEO-CM04S1, a vaccine candidate that is in Phase 2 clinical trial for the treatment of preventive COVID-19; Gedeptin, a novel patented product/technology for the treatment of solid tumors, and Phase 1/2 clinical trial for the treatment of advanced head and neck squamous cell carcinoma; and GEO-CM02, a pan-coronavirus vaccine. In addition, the company offers GEO-MVA-MUC1, a vaccine candidate, which is in preclinical trial for the treatment of solid tumor cancers; GEO-ZM02, a vaccine candidate, which is in preclinical trial for the treatment of Zika; GEO-EMO1-Z, which is in preclinical trial for the treatment of Ebola Zaire; GEO-EMO1-S, which is in preclinical trial for the treatment of Ebola Sudan; GEO-MM01 treatment for marburg; and GEO-MVA for the treatment of Mpox and small pox. It has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; U.S. Department of Defense; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is headquartered in Smyrna, Georgia.
Fundamentals
Scroll to Statements| Market Cap | 3.38M | Enterprise Value | 1.14M | Income | -21.46M | Sales | 2.49M | Book/sh | 4.13 | Cash/sh | 1.07 |
| Dividend Yield | — | Payout | 0.00% | Employees | — | IPO | — | P/E | — | Forward P/E | -1.36 |
| PEG | — | P/S | 1.36 | P/B | 0.28 | P/C | — | EV/EBITDA | -0.05 | EV/Sales | 0.46 |
| Quick Ratio | 1.59 | Current Ratio | 2.74 | Debt/Eq | 22.04 | LT Debt/Eq | — | EPS (ttm) | -22.40 | EPS next Y | -0.86 |
| EPS Growth | — | Revenue Growth | -100.00% | Earnings | 2026-03-23 | ROA | -186.57% | ROE | -4.84% | ROIC | — |
| Gross Margin | 0.00% | Oper. Margin | -8.69% | Profit Margin | 0.00% | Shs Outstand | 2.89M | Shs Float | 2.89M | Short Float | 9.09% |
| Short Ratio | 3.88 | Short Interest | — | 52W High | 34.75 | 52W Low | 1.12 | Beta | 3.81 | Avg Volume | 112.28K |
| Volume | 74.78K | Target Price | $77.50 | Recom | Strong_buy | Prev Close | $1.14 | Price | $1.17 | Change | 2.63% |
Valuation Models
Price estimates from analyst targets and simple models.
Ratings
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-04-16 | main | D. Boral Capital | Hold → Hold | $1 |
| 2026-02-19 | down | D. Boral Capital | Buy → Hold | — |
| 2026-01-21 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-11-19 | main | D. Boral Capital | Buy → Buy | $6 |
| 2025-09-26 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-08-07 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-07-29 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-07-17 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-06-16 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-05-02 | main | D. Boral Capital | Buy → Buy | $9 |
| 2025-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2025-04-15 | main | D. Boral Capital | Buy → Buy | $14 |
| 2025-04-10 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-03-28 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-02-27 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-01-31 | main | D. Boral Capital | Buy → Buy | $18 |
| 2025-01-16 | main | D. Boral Capital | Buy → Buy | $18 |
| 2024-12-18 | main | D. Boral Capital | Buy → Buy | $18 |
| 2024-11-20 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-11-19 | main | D. Boral Capital | Buy → Buy | $18 |
- [EFFECT] GeoVax Labs, Inc. SEC Filing - Stock Titan Wed, 22 Apr 2026 10
- How The Story On GeoVax Labs (GOVX) Is Shifting Toward Execution Risk And Funding Constraints - Yahoo Finance Wed, 11 Mar 2026 07
- GOVX Should I Buy - Intellectia AI Fri, 17 Apr 2026 07
- $GOVX stock is down 25% today. Here's what we see in our data. - Quiver Quantitative ue, 30 Sep 2025 07
- GeoVax Labs (GOVX) Stock vs Peers (Edges Lower) 2026-04-16 - Scalping - Xã Vĩnh Công hu, 16 Apr 2026 10
- GOVX SEC Filings - Geovax Labs Inc 10-K, 10-Q, 8-K Forms - Stock Titan Wed, 22 Apr 2026 03
- GOVX Maintained by D. Boral Capital -- Price Target Steady at $1 - GuruFocus hu, 16 Apr 2026 17
- Why The GeoVax Labs (GOVX) Story Is Shifting As Valuation Holds And Risks Rise - Yahoo Finance ue, 31 Mar 2026 07
- Geovax Labs (GOVX) Receives "Buy" Rating Again from D. Boral Cap - GuruFocus Wed, 21 Jan 2026 08
- GeoVax Labs (NASDAQ: GOVX) adds auditor consent in S-1 amendment - Stock Titan Fri, 17 Apr 2026 13
- GeoVax Labs (GOVX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance Wed, 20 Aug 2025 07
- GeoVax Labs (NASDAQ: GOVX) seeks votes to approve Feb/March 2026 warrant exercises - Stock Titan hu, 16 Apr 2026 20
- GeoVax (Nasdaq: GOVX) trims 2025 loss while advancing GEO-MVA to Phase 3 - Stock Titan Wed, 15 Apr 2026 21
- GeoVax Labs (NASDAQ: GOVX) investors face going concern, dilution risks - Stock Titan Wed, 15 Apr 2026 21
- How The GeoVax Labs (GOVX) Story Is Shifting After The Rating Downgrade And Valuation Reset - Yahoo Finance ue, 14 Apr 2026 07
Insider Transactions
Financials
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
2.49
-37.06%
|
3.95
|
0.00
-100.00%
|
0.08
|
| Operating Revenue |
|
2.49
-37.06%
|
3.95
|
0.00
-100.00%
|
0.08
|
| Operating Expense |
|
24.13
-17.08%
|
29.10
+8.81%
|
26.74
+89.53%
|
14.11
|
| Research And Development |
|
18.12
-23.58%
|
23.71
+14.44%
|
20.72
+127.11%
|
9.12
|
| Selling General And Administration |
|
6.01
+11.54%
|
5.39
-10.58%
|
6.02
+20.77%
|
4.99
|
| General And Administrative Expense |
|
6.01
+11.54%
|
5.39
-10.58%
|
6.02
+20.77%
|
4.99
|
| Other Gand A |
|
6.01
+11.54%
|
5.39
-10.58%
|
6.02
+20.77%
|
4.99
|
| Total Expenses |
|
24.13
-17.08%
|
29.10
+8.81%
|
26.74
+89.53%
|
14.11
|
| Operating Income |
|
-21.64
+13.94%
|
-25.14
+5.98%
|
-26.74
-90.63%
|
-14.03
|
| Total Operating Income As Reported |
|
-21.64
+13.94%
|
-25.14
+5.98%
|
-26.74
-90.63%
|
-14.03
|
| EBITDA |
|
-21.40
+13.99%
|
-24.88
+3.93%
|
-25.89
-85.31%
|
-13.97
|
| Normalized EBITDA |
|
-21.40
+13.99%
|
-24.88
+3.93%
|
-25.89
-85.31%
|
-13.97
|
| Reconciled Depreciation |
|
0.07
-27.90%
|
0.10
+28.58%
|
0.07
+31.78%
|
0.06
|
| EBIT |
|
-21.46
+14.04%
|
-24.97
+3.84%
|
-25.97
-85.10%
|
-14.03
|
| Total Unusual Items |
|
—
|
—
|
—
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
—
|
—
|
—
|
0.00
|
| Special Income Charges |
|
—
|
—
|
—
|
0.00
|
| Other Special Charges |
|
—
|
—
|
—
|
—
|
| Net Income |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Pretax Income |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Net Non Operating Interest Income Expense |
|
0.17
+14.67%
|
0.15
-80.42%
|
0.78
+10333.89%
|
0.01
|
| Interest Expense Non Operating |
|
0.00
-100.00%
|
0.02
|
0.00
|
0.00
|
| Net Interest Income |
|
0.17
+14.67%
|
0.15
-80.42%
|
0.78
+10333.89%
|
0.01
|
| Interest Expense |
|
0.00
-100.00%
|
0.02
|
0.00
|
0.00
|
| Interest Income Non Operating |
|
0.17
+0.53%
|
0.17
-77.67%
|
0.78
+10333.89%
|
0.01
|
| Interest Income |
|
0.17
+0.53%
|
0.17
-77.67%
|
0.78
+10333.89%
|
0.01
|
| Other Income Expense |
|
—
|
—
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Net Income From Continuing Operation Net Minority Interest |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Net Income From Continuing And Discontinued Operation |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Net Income Continuous Operations |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Normalized Income |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Net Income Common Stockholders |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Diluted EPS |
|
—
|
-120.46
+66.28%
|
-357.25
-14.78%
|
-311.25
|
| Basic EPS |
|
—
|
-120.46
+66.28%
|
-357.25
-14.78%
|
-311.25
|
| Basic Average Shares |
|
—
|
0.21
+185.43%
|
0.07
+60.60%
|
0.05
|
| Diluted Average Shares |
|
—
|
0.21
+185.43%
|
0.07
+60.60%
|
0.05
|
| Diluted NI Availto Com Stockholders |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
9.28
|
| Current Assets |
|
7.89
|
| Cash Cash Equivalents And Short Term Investments |
|
6.45
|
| Cash And Cash Equivalents |
|
6.45
|
| Receivables |
|
0.00
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
1.43
|
| Other Current Assets |
|
—
|
| Total Non Current Assets |
|
1.40
|
| Net PPE |
|
0.21
|
| Gross PPE |
|
0.89
|
| Accumulated Depreciation |
|
-0.68
|
| Properties |
|
0.00
|
| Buildings And Improvements |
|
—
|
| Machinery Furniture Equipment |
|
0.77
|
| Leases |
|
0.12
|
| Goodwill And Other Intangible Assets |
|
0.07
|
| Other Intangible Assets |
|
0.07
|
| Non Current Prepaid Assets |
|
1.12
|
| Other Non Current Assets |
|
1.19
|
| Total Liabilities Net Minority Interest |
|
3.52
|
| Current Liabilities |
|
3.52
|
| Payables And Accrued Expenses |
|
3.52
|
| Payables |
|
2.80
|
| Accounts Payable |
|
2.80
|
| Current Accrued Expenses |
|
0.72
|
| Current Debt And Capital Lease Obligation |
|
—
|
| Current Capital Lease Obligation |
|
—
|
| Total Non Current Liabilities Net Minority Interest |
|
0.00
|
| Long Term Debt And Capital Lease Obligation |
|
—
|
| Long Term Capital Lease Obligation |
|
—
|
| Other Non Current Liabilities |
|
—
|
| Stockholders Equity |
|
5.76
|
| Common Stock Equity |
|
5.76
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
—
|
| Share Issued |
|
0.08
|
| Ordinary Shares Number |
|
0.08
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
110.13
|
| Retained Earnings |
|
-104.36
|
| Total Equity Gross Minority Interest |
|
5.76
|
| Total Capitalization |
|
5.76
|
| Working Capital |
|
4.37
|
| Invested Capital |
|
5.76
|
| Total Debt |
|
—
|
| Capital Lease Obligations |
|
—
|
| Net Tangible Assets |
|
5.69
|
| Tangible Book Value |
|
5.69
|
| Non Current Accrued Expenses |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-21.47
+12.97%
|
-24.68
+1.98%
|
-25.17
-32.28%
|
-19.03
|
| Cash Flow From Continuing Operating Activities |
|
-21.47
+12.97%
|
-24.68
+1.98%
|
-25.17
-32.28%
|
-19.03
|
| Net Income From Continuing Operations |
|
-21.46
+14.11%
|
-24.99
+3.75%
|
-25.97
-85.20%
|
-14.02
|
| Depreciation Amortization Depletion |
|
0.07
-27.90%
|
0.10
+28.58%
|
0.07
+31.78%
|
0.06
|
| Depreciation |
|
0.07
|
—
|
0.07
+31.78%
|
0.06
|
| Depreciation And Amortization |
|
0.07
-27.90%
|
0.10
+28.58%
|
0.07
+31.78%
|
0.06
|
| Stock Based Compensation |
|
1.12
+110.95%
|
0.53
-50.82%
|
1.07
+19.17%
|
0.90
|
| Operating Gains Losses |
|
—
|
—
|
—
|
—
|
| Gain Loss On Investment Securities |
|
—
|
—
|
—
|
—
|
| Change In Working Capital |
|
-1.19
-288.35%
|
-0.31
+13.70%
|
-0.36
+94.03%
|
-5.97
|
| Change In Receivables |
|
0.66
+200.00%
|
-0.66
|
0.00
-100.00%
|
0.05
|
| Change In Prepaid Assets |
|
-0.41
-17.75%
|
-0.35
-207.50%
|
-0.11
+90.18%
|
-1.17
|
| Change In Payables And Accrued Expense |
|
-1.47
-255.25%
|
-0.41
+66.41%
|
-1.23
+54.31%
|
-2.69
|
| Change In Other Working Capital |
|
—
|
—
|
—
|
-2.16
|
| Change In Other Current Assets |
|
0.03
-97.53%
|
1.12
+13.21%
|
0.99
+145.60%
|
-2.16
|
| Investing Cash Flow |
|
-0.03
-33.69%
|
-0.02
+57.80%
|
-0.05
+63.54%
|
-0.13
|
| Cash Flow From Continuing Investing Activities |
|
-0.03
-33.69%
|
-0.02
+57.80%
|
-0.05
+63.54%
|
-0.13
|
| Net PPE Purchase And Sale |
|
-0.03
-33.69%
|
-0.02
+57.80%
|
-0.05
+63.54%
|
-0.13
|
| Purchase Of PPE |
|
-0.03
-33.69%
|
-0.02
+57.80%
|
-0.05
+63.54%
|
-0.13
|
| Capital Expenditure |
|
-0.03
-33.69%
|
-0.02
+57.80%
|
-0.05
+63.54%
|
-0.13
|
| Financing Cash Flow |
|
19.08
-19.66%
|
23.75
+484.64%
|
4.06
-88.51%
|
35.35
|
| Cash Flow From Continuing Financing Activities |
|
19.08
-19.66%
|
23.75
+484.64%
|
4.06
-88.51%
|
35.35
|
| Net Issuance Payments Of Debt |
|
0.00
+100.00%
|
-0.01
|
0.00
|
0.00
|
| Issuance Of Debt |
|
0.00
-100.00%
|
0.14
|
0.00
|
—
|
| Repayment Of Debt |
|
0.00
+100.00%
|
-0.15
|
0.00
|
0.00
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Long Term Debt Payments |
|
—
|
—
|
—
|
0.00
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
0.00
|
| Short Term Debt Issuance |
|
0.00
-100.00%
|
0.14
|
0.00
|
—
|
| Short Term Debt Payments |
|
0.00
+100.00%
|
-0.15
|
0.00
|
0.00
|
| Net Short Term Debt Issuance |
|
0.00
+100.00%
|
-0.01
|
0.00
|
0.00
|
| Net Common Stock Issuance |
|
18.92
-11.56%
|
21.40
|
0.00
-100.00%
|
27.73
|
| Repurchase Of Capital Stock |
|
—
|
—
|
—
|
0.00
|
| Proceeds From Stock Option Exercised |
|
0.16
-93.40%
|
2.37
-41.73%
|
4.06
-46.73%
|
7.63
|
| Changes In Cash |
|
-2.42
-156.04%
|
-0.95
+95.53%
|
-21.16
-230.71%
|
16.19
|
| Beginning Cash Position |
|
5.51
-14.66%
|
6.45
-76.63%
|
27.61
+141.71%
|
11.42
|
| End Cash Position |
|
3.09
-43.97%
|
5.51
-14.66%
|
6.45
-76.63%
|
27.61
|
| Free Cash Flow |
|
-21.50
+12.94%
|
-24.70
+2.09%
|
-25.22
-31.61%
|
-19.16
|
| Common Stock Issuance |
|
18.92
-11.56%
|
21.40
|
0.00
-100.00%
|
27.73
|
| Issuance Of Capital Stock |
|
18.92
-11.56%
|
21.40
|
0.00
-100.00%
|
27.73
|
| Net Preferred Stock Issuance |
|
—
|
—
|
—
|
0.00
|
| Preferred Stock Issuance |
|
—
|
—
|
—
|
—
|
| Preferred Stock Payments |
|
—
|
—
|
—
|
0.00
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 8-K2026-04-15 View
- 10-K2026-04-15 View
- 8-K2026-03-31 View
- 8-K2026-02-17 View
- 8-K2026-01-12 View
- 8-K2025-12-22 View
- 8-K2025-11-26 View
- 8-K2025-11-13 View
- 10-Q2025-11-13 View
- 42025-10-20 View
- 8-K2025-09-30 View
- 42025-08-08 View
- 8-K2025-08-01 View
- 8-K2025-07-29 View
- 10-Q2025-07-28 View
- 8-K2025-07-02 View
- 42025-06-06 View
- 42025-06-06 View
- 42025-06-06 View
- 42025-06-06 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|